

# Youngjoo Lee

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7266892/publications.pdf>

Version: 2024-02-01

23  
papers

397  
citations

1040056

9  
h-index

752698

20  
g-index

23  
all docs

23  
docs citations

23  
times ranked

694  
citing authors

#	ARTICLE	IF	CITATIONS
1	Long-term outcomes in patients with advanced and/or metastatic non-small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: Multicenter, real-world data (KCSG LU2011). <i>Cancer</i> , 2022, 128, 778-787.	4.1	23
2	A Phase 1/2 Study of Lazertinib 240 mg in Patients With Advanced EGFR T790M-Positive NSCLC After Previous EGFR Tyrosine Kinase Inhibitors. <i>Journal of Thoracic Oncology</i> , 2022, 17, 558-567.	1.1	43
3	Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. <i>Cancers</i> , 2022, 14, 1512.	3.7	1
4	A Comparative Analysis of Photon versus Proton Beam Therapy in Neoadjuvant Concurrent Chemoradiotherapy for Intrathoracic Squamous Cell Carcinoma of the Esophagus at a Single Institute. <i>Cancers</i> , 2022, 14, 2033.	3.7	2
5	A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 213-222.	2.5	8
6	Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 151, 8-15.	2.0	23
7	Evaluation of Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Screening and Monitoring Biomarkers for Brain Metastases. <i>Cancers</i> , 2021, 13, 2227.	3.7	3
8	Photon Versus Proton Beam Therapy for T1-3 Squamous Cell Carcinoma of the Thoracic Esophagus Without Lymph Node Metastasis. <i>Frontiers in Oncology</i> , 2021, 11, 699172.	2.8	6
9	One-Step Polymerase Chain Reaction-Free Nanowire-Based Plasma Cell-Free DNA Assay to Detect EML4-ALK Fusion and to Monitor Resistance in Lung Cancer. <i>Oncologist</i> , 2021, 26, e1683-e1692.	3.7	2
10	Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis. <i>Cancer Research and Treatment</i> , 2021, 53, 77-86.	3.0	8
11	Phase II Study of Pemetrexed as a Salvage Chemotherapy for Thymidylate Synthase-Low Squamous Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2021, 53, 87-92.	3.0	0
12	Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis. <i>Targeted Oncology</i> , 2020, 15, 513-522.	3.6	2
13	The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma. <i>Lung Cancer</i> , 2019, 136, 15-22.	2.0	6
14	De novo cystic brain lesions mimicking neurocysticercosis in ALK-positive lung cancer. <i>Lung Cancer</i> , 2017, 110, 53-55.	2.0	6
15	Effect of Accurate Staging Using Positron Emission Tomography on the Outcomes of Prophylactic Cranial Irradiation in Patients With Limited Stage Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 77-84.	2.6	8
16	Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Nonadenocarcinomatous Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2017, 49, 1001-1011.	3.0	43
17	The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation. <i>Oncotarget</i> , 2016, 7, 43315-43323.	1.8	6
18	Clinical Likelihood of Sporadic Primary EGFR T790M Mutation in EGFR-Mutant Lung Cancer. <i>Clinical Lung Cancer</i> , 2015, 16, 46-50.	2.6	26

#	ARTICLE	IF	CITATIONS
19	Systemic Nocardiosis Mimicking Disease Flare-up after Discontinuation of Gefitinib in a Patient with EGFR-Mutant Lung Cancer. <i>Tuberculosis and Respiratory Diseases</i> , 2014, 77, 271.	1.8	1
20	Clinical outcome according to the level of preexisting epidermal growth factor receptor T790M mutation in patients with lung cancer harboring sensitive epidermal growth factor receptor mutations. <i>Cancer</i> , 2014, 120, 2090-2098.	4.1	57
21	Clinical Significance of Heterogeneity in Response to Retreatment With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Lung Cancer Acquiring Secondary Resistance to the Drug. <i>Clinical Lung Cancer</i> , 2014, 15, 145-151.	2.6	19
22	Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung. <i>Journal of Neuro-Oncology</i> , 2013, 115, 95-101.	2.9	30
23	Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 2009-2016.	2.5	74